| Prairie Health Clinic | |
|
708 8th St Armour SD 57313-2102 | |
| (605) 724-2151 | |
| (605) 724-2310 |
| Full Name | Prairie Health Clinic |
|---|---|
| Speciality | Clinic/Center |
| Location | 708 8th St, Armour, South Dakota |
| Authorized Official Name and Position | Nicole J Neugebauer (CLINIC OFFICE MANAGER) |
| Authorized Official Contact | 6057242151 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Prairie Health Clinic 708 8th St Armour SD 57313-2102 Ph: (605) 724-2151 | Prairie Health Clinic 708 8th St Armour SD 57313-2102 Ph: (605) 724-2151 |
| NPI Number | 1174516124 |
|---|---|
| Provider Enumeration Date | 08/25/2005 |
| Last Update Date | 10/19/2007 |
| Medicare PECOS PAC ID | 7810889771 |
|---|---|
| Medicare Enrollment ID | O20041029000768 |
News Archive
Though worlds apart, four unrelated families have been united in a medical mystery over the source of a rare inherited disorder that results in their children being born with abnormal brain growth and severe functional impairments.
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
Researchers from VIB-UGent reveal that adult circulating monocytes that get access to the macrophage niche in the liver or the lung can acquire identical tissue-specific macrophage functions and self-maintenance capacities as macrophages of embryonic origin.
Neuroene Therapeutics, a start-up company founded by mitochondrial biologist Sherine S. L. Chan, Ph.D. and medicinal chemist C. James Chou, Ph.D. of the Medical University of South Carolina, has received a $1.5 million NIH Phase II Small Business Innovation Research grant to optimize vitamin K analogues that could improve seizure control in patients with drug-resistant epilepsy.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174516124 | NPI | - | NPPES |
| 5300600 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
News Archive
Though worlds apart, four unrelated families have been united in a medical mystery over the source of a rare inherited disorder that results in their children being born with abnormal brain growth and severe functional impairments.
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
Researchers from VIB-UGent reveal that adult circulating monocytes that get access to the macrophage niche in the liver or the lung can acquire identical tissue-specific macrophage functions and self-maintenance capacities as macrophages of embryonic origin.
Neuroene Therapeutics, a start-up company founded by mitochondrial biologist Sherine S. L. Chan, Ph.D. and medicinal chemist C. James Chou, Ph.D. of the Medical University of South Carolina, has received a $1.5 million NIH Phase II Small Business Innovation Research grant to optimize vitamin K analogues that could improve seizure control in patients with drug-resistant epilepsy.
› Verified 6 days ago
Prairie Health Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 708 8th St, Armour, SD 57313 Phone: 605-724-2151 Fax: 605-724-2310 |